Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H29NO5.ClH |
Molecular Weight | 387.898 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1
InChI
InChIKey=VKFAUCPBMAGVRG-UHFFFAOYSA-N
InChI=1S/C19H29NO5.ClH/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6;/h8-10,13,20-21H,11H2,1-7H3;1H
Molecular Formula | C19H29NO5 |
Molecular Weight | 351.4373 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00449Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/18239s25lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00449
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/18239s25lbl.pdf
Dipivefrin is a prodrug with little or no pharmacologically activity until it is hydrolyzed into epinephrine inside the human eye. The liberated epinephrine, an adrenergic agonist, appears to exert its action by stimulating α -and/or β2-adrenergic receptors, leading to a decrease in aqueous production and an enhancement of outflow facility. The dipivefrin prodrug delivery system is a more efficient way of delivering the therapeutic effects of epinephrine, with fewer side effects than are associated with conventional epinephrine therapy. Dipivefrin is used as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00449 |
|||
Target ID: CHEMBL1867 Sources: http://www.drugbank.ca/drugs/DB00449 |
|||
Target ID: CHEMBL210 Sources: http://www.drugbank.ca/drugs/DB00449 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROPINE Approved UsePROPINE (dipivefrin HCI ophthalmic solution, USP) is indicated as initial therapy for the control of intraocular pressure in chronic
open-angle glaucoma. Launch Date1980 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8446367/ Page: - |
yes [IC50 3000 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8446367/ Page: - |
yes [Km 1030 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8446367/ Page: - |
yes [Km 1410 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8446367/ Page: - |
yes [Km 2160 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
External ocular toxicity of dipivalyl epinephrine. | 1979 Dec |
|
Systemic hypertension in patients receiving dipivalyl adrenaline for glaucoma. | 1988 Sep 17 |
|
Central vein thrombosis and topical dipivalyl epinephrine. | 1990 Aug |
|
Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. | 1998 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/dipivefrin.html
Initial Glaucoma Therapy
The usual dosage of Dipivefrin Hydrochloride Ophthalmic Solution 0.1% is one drop in the eye(s) every 12 hours.
Route of Administration:
Irrigation
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8282042
Dipivefrin caused a reduction in bovine trabecular cell density at concentration 103-260 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:29:53 GMT 2023
by
admin
on
Fri Dec 15 17:29:53 GMT 2023
|
Record UNII |
5QTH9UHV0K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29705
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71486
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
SUB01790MIG
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
C47495
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
64019-93-8
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
DBSALT000626
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
48086
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
DTXSID2045494
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
4647
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
m4648
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
5QTH9UHV0K
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
203156
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000093057
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201262
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
264-609-5
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY | |||
|
5QTH9UHV0K
Created by
admin on Fri Dec 15 17:29:53 GMT 2023 , Edited by admin on Fri Dec 15 17:29:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
PARENT -> SALT/SOLVATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Limit of 5-Pivaloyl racepinephrine and 4-Pivaloyl racepinephrine not more than 0.3%
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |